Business
Tempus Achieves Record Total Contract Value Exceeding $1.1 Billion
CHICAGO, January 11, 2026--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a record Total Contract Value (TCV) of >$1.1 billion as of December 31, 2025. During 2025, Tempus signed data agreements with over 70 customers, spanning both large and mid-sized pharma, including AstraZeneca, GlaxoSmithKline, Bristol Myers Squibb, Pfizer, Novartis, Merck, Abbvie, Daiichi Sankyo, Eli Lilly, Boehringer Ingelheim, and biotechs inc
About this update from Bristol-myers Squibb Company
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/5ef6c4c591b248a3412b0a0ddce16d95"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/9i_L0TzQIek1r4EbPU3H3Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/5ef6c4c591b248a3412b0a0ddce16d95","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/6sx9A3YDChAfhQNcClOrmg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/5ef6c4c591b248a3412b0a0ddce16d95","width":1024,"height":512}},"lazy":false},{"type":"text","content":"Reported preliminary, unaudited Data and application revenue of ~$316 million for the full year 2025, representing ~31% year-over-year growth, with Insights (data licensing) growing 38%","length":185,"tagName":"p"},{"type":"text","content":"2025 Net revenue retention of ~126%","length":35,"tagName":"p"},{"type":"text","content":"CHICAGO, January 11, 2026--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a record Total Contract Value (TCV) of >$1.1 billion as of December 31, 2025. During 2025, Tempus signed data agreements with over 70 customers, spanning both large and mid-sized pharma, including AstraZeneca, GlaxoSmithKline, Bristol Myers Squibb, Pfizer, Novartis, Merck, Abbvie, Daiichi Sankyo, Eli Lilly, Boehringer Ingelheim, and biotechs including Incyte, Servier, Aspera Biomedicines, and Whitehawk Therapeutics, as an increasing number of biopharma companies are incorporating Tempus’ unique, multimodal dataset into their drug discovery and development efforts.","length":743,"tagName":"p"},{"type":"text","content":"In addition to TCV rising to the highest level in Tempus’s history, the company reported net revenue retention of ~126% in 2025, demonstrating the continued expansion of relationships with existing customers, even at increased scale.","length":233,"tagName":"p"},{"type":"text","content":""2025 was a record year for our Data and applications business - both from a revenue and TCV perspective," said Jim Rogers, Chief Financial Officer at Tempus. "Our engagement with life science...